Furthermore, the effectiveness and safety of immune checkpoint inhibitors, such as pembrolizumab and camrelizumab, which block immune evasion through the PD-1/PD-L1 pathway, have been proven in several prior studies for advanced HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.